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S U M M A R Y
Objectives: To evaluate the performance of the newly developed technology Abbott RealTime MTB assay
(RealTime MTB assay) for the detection of Mycobacterium tuberculosis in sputum specimens and to
compare its performance with that of the Cepheid GeneXpert assay.
Methods: Sputum specimens were collected from 270 subjects suspected to have tuberculosis (TB).
Smear microscopy, culture, identiﬁcation, RealTime MTB, and GeneXpert assays were performed
according to standard protocols. Accuracy measures of the method evaluated were determined using
solid culture as the reference standard.
Results: The RealTime MTB assay showed similar positive detection rates as the GeneXpert assay in
smear-positive, culture-positive, and smear/culture-negative groups; no signiﬁcant differences were
found in these groups between the two assays. The RealTime MTB assay demonstrated a sensitivity of
100% and a speciﬁcity of 84.4%; the GeneXpert assay had a sensitivity of 96.9% and speciﬁcity of 89.6%.
After the resolution of discordant results by PCR-based molecular method, the sensitivities and
speciﬁcities of the RealTime MTB and GeneXpert assays were 100% vs. 97% and 90.0% vs. 95.6%,
respectively; no signiﬁcant difference in sensitivity or speciﬁcity was found between the RealTime MTB
and GeneXpert assays.
Conclusions: This study demonstrated that the Abbott RealTime MTB and Cepheid GeneXpert assays
have similar sensitivity and speciﬁcity. The Abbott RealTime MTB assay is a highly promising method for
the diagnosis of TB.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Tuberculosis (TB) is one of the major infectious diseases in
resource-limited countries. China is one of the 22 high TB burden
countries and is facing the great challenge of epidemic TB and
multidrug-resistant TB.1 Data from the Fifth National Tuberculosis
Prevalence Survey in China indicated that the prevalence of active
pulmonary TB was 459/100 000 and that 43.1% of active
pulmonary TB patients had no pulmonary TB symptoms.2 At
present, smear microscopy and chest X-ray are commonly used for* Corresponding author.
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).the detection of TB in most county-level TB clinics and TB
dispensaries in China. Due to the poor speciﬁcity of chest X-ray and
the relatively low sensitivity of the smear test, the diagnosis of
smear-negative pulmonary TB is more difﬁcult than that of smear-
positive pulmonary TB; therefore, missed diagnosis or a misdiag-
nosis of TB is easy.3–5
In order to increase case ﬁnding and decrease the spread of TB,
new sensitive TB diagnostic methods are urgently needed in China.
The Cepheid GeneXpert MTB/RIF assay (Cepheid, Sunnyvale,
California, USA) endorsed by the World Health Organization is a
promising new rapid diagnostic technology and this assay has been
used in some county-level laboratories in China.6 A previous study
showed the GeneXpert assay to be a sensitive and speciﬁc
method for the initial detection of Mycobacterium tuberculosis
and that it may also be a valuable add-on test for patients with aciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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Molecular, Des Plaines, IL, USA) is a recently developed technology
designed to produce results relatively quickly, with little hands-
on-time required. This test could be useful in high TB burden
countries. In this study, the Abbott RealTime assay for the
detection of M. tuberculosis in sputum was evaluated and its
performance was compared with that of the Cepheid GeneXpert
assay.
2. Methods
Sputum specimens were collected from patients with suspected
pulmonary TB at TB clinics between March and December
2014. One specimen was provided by each TB patient for this
study. Sputum smear test was performed at national TB reference
laboratory. Following the smear test, the left-over sputum samples
were stored at 20 8C until culture, identiﬁcation, GeneXpert, and
RealTime MTB assays were performed. Sputum smear microscopy
(Ziehl–Neelsen staining), culture, and identiﬁcation were per-
formed according to standard protocols.8 The GeneXpert assay and
the RealTime MTB assay were performed according to the
manufacturer’s standard protocols. Accuracy measures, including
sensitivity, speciﬁcity, and positive and negative predictive values
of the method evaluated, were determined using solid culture as
the reference standard. Samples for which there were smear,
culture, identiﬁcation, GeneXpert, and RealTime MTB assay results
were included in the analysis.
McNemar’s Chi-square test or exact probability for paired four-
fold tables was performed for the comparison of categorical data.
Cohen’s kappa score was used to test the agreement of the different
assays. The statistical analysis was performed using IBM SPSS
Statistics version 20.0 (IBM Corp., Armonk, NY, USA) and Epi Info
version 3.5.1 (US Centers for Disease Control and Prevention,
Atlanta, GA, USA). This study was approved by the Chinese Center
for Disease Control and Prevention.Figure 1. Summary of the study plan, 3. Results
Two hundred and seventy sputum specimens were collected
from patients with suspected pulmonary TB. Due to inadequate
sample volumes for the performance of all of the tests (10 sputum
samples) or culture contamination (ﬁve sputum samples), only
255 samples with complete results were included in the analysis.
Of the 255 samples, 161 (63.1%) were smear-positive, 159 (62.4%)
were culture-positive, and 89 (34.9%) were smear-negative and
culture-negative (Fig. 1). The RealTime MTB assay showed similar
positive detection rates as the GeneXpert assay in the smear-
positive, culture-positive, and smear/culture-negative groups; no
signiﬁcant differences were observed between the RealTime MTB
and GeneXpert assays in these groups (Table 1).
The sensitivity of the RealTime MTB assay compared to solid
culture was 100% (95% conﬁdence interval (CI) 98.6–99.9%), the
speciﬁcity was 84.4% (95% CI 75.5–91.0%), the positive predictive
value (PPV) was 91.4%, and the negative predictive value (NPV) was
100%. GeneXpert demonstrated a sensitivity of 96.9% (95% CI 92.8–
99.0%), a speciﬁcity of 89.6% (95% CI 81.7–94.9%), a PPV of 93.9%,
and an NPV of 94.5%. Six of the 15 discordant specimens (RealTime
MTB and GeneXpert assays positive but culture-negative) tested by
16S–23S rDNA internal transcribed spacer (ITS) sequencing were
conﬁrmed positive. When these six patients were combined with
the culture-positive TB group and the data reanalyzed, the
speciﬁcities of the RealTime MTB and GeneXpert increased to
90.0% and 95.6%, respectively (Table 2). The kappa score between
the RealTime MTB and GeneXpert assays was 0.8949 (95% CI
0.8371–0.9527).
4. Discussion
The Abbott RealTime MTB assay was evaluated and compared
to the Cepheid GeneXpert test to determine if this new test could
be used to detect M. tuberculosis in sputum. The RealTime MTBsample processing, and outcomes.
Table 1
Positive detection rates of the Abbott RealTime MTB and Cepheid GeneXpert assays for the sputum specimens used in this study
Smear/culture
result









S+ 161 (63.1) 100.0 (98.6–99.9) 96.9 (92.9–99.0) 0.0625
C+ 159 (62.4) 100.0 (98.6–99.9) 96.9 (92.8–99.0) 0.0625
S+/C+ 154 (60.4) 100.0 (98.6–99.9) 96.8 (92.6–98.9) 0.0625
S+/C 7 (2.7) 100.0 (71.7–96.8) 100.0 (71.7–96.8) 1.0000
S/C+ 5 (2.0) 100.0 (62.0–95.5) 100.0 (62.0–95.5) 1.0000
S/C 89 (34.9) 9.0 (4.0–16.9) 3.4 (0.7–9.5) 0.1250
CI, conﬁdence interval; S+, smear-positive; S, smear-negative; C+, culture-positive; C, culture-negative.
a Exact probability for paired four-fold tables.
Table 2
Performance of the Abbott RealTime MTB and Cepheid GeneXpert assays for sputum specimens before and after resolution testing of discordant specimens by 16S–23S ITS
sequencing
Assay No. of specimens
tested
No. of specimens with indicated result % Sensitivity (CI)a % Speciﬁcity (CI)b % PPV % NPV
R+/C+ R/C R+/C R/C+
Before resolution of discordant results
RealTime MTB 255 159 81 0 15 100 (98.6–99.9) 84.4 (75.5–91.0) 91.4 100.0
GeneXpert 255 154 86 5 10 96.9 (92.8–99.0) 89.6 (81.7–94.9) 93.9 94.5
After resolution of discordant results
RealTime MTB 255 165 81 0 9 100 (98.7–99.9) 90.0 (81.9–95.3) 94.8 100.0
GeneXpert 255 160 86 5 4 97.0 (93.1–99.0) 95.6 (89.0–98.8) 97.6 94.5
ITS, internal transcribed spacer; R, reference method (solid culture) result; C, comparative method result; +, positive result; , negative result; CI, 95% conﬁdence interval;
PPV, positive predictive value; NPV, negative predictive value.
a Comparison of sensitivities between RealTime MTB and GeneXpert tests before and after the resolution of discordant results: p = 0.0625 and P = 0.0625, respectively
(exact probability for paired four-fold tables).
b Comparison of speciﬁcities between RealTime MTB and GeneXpert tests before and after the resolution of discordant results: p = 0.1250 and p = 0.0625, respectively (exact
probability for paired four-fold tables).
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GeneXpert assay, with a kappa score of 0.8949, showing a good
agreement. After conﬁrmation testing by 16S–23S rDNA ITS
sequencing of the six discordant specimens, the speciﬁcity and
PPV of the RealTime MTB increased to 90.0% and 94.8%, respectively.
The GeneXpert assay speciﬁcity increased from 89.6% to 95.6%.
This study has some limitations. Solid culture, which was
performed on frozen archived specimens, was used as the
reference standard in this study. This may have reduced the
speciﬁcity and PPV of the methods evaluated.9 The assessment of
sensitivity and speciﬁcity in this study was performed in reference
laboratories during research investigations, and this evaluation
was not a multicenter clinical trial. Feasibility and a cost analysis
were not considered in this study. Further investigations should
evaluate the diagnostic accuracy and clinical impact of the Abbott
RealTime MTB assay in routine health care settings in prospective
studies with fresh samples.
In conclusion, this study demonstrated that the Abbott
RealTime MTB assay has comparable sensitivity and speciﬁcity
to the Cepheid GeneXpert assay for the detection of M. tuberculosis
in sputum specimens. This preliminary study suggests that the
Abbott assay may be a promising method with broader utility for
the diagnosis of TB in high TB burden countries.
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